Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2124-2131

  Rampias, T ^a   Pectasides, E ^a   Prasad, M ^a   Sasaki, C ^a   Gouveris, P ^a   Dimou, A ^a   Kountourakis, P ^a   Perisanidis, C ^b   Burtness, B ^c   Zaramboukas, T ^d   Rimm, D ^a   Fountzilas, G ^d   Psyrri, A ^a,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c FOX CHASE CANCER CENTER   (United States)

^d PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

EGFR; HNSCC; Wnt

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN E6; PROTEIN E7; PROTEIN P110; PROTEIN P15; UVOMORULIN;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; E6 GENE; E7 GENE; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE MICROARRAY; UPREGULATION; VIRUS IDENTIFICATION; WART VIRUS;

EGFR; HNSCC; P16+; WNT;

BETA CATENIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, VIRAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 84881219523     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt013     Document Type: Article

References (22)

1. Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 2002; 9: 387-399.
2. Argiris A, Karamouzis MV, Raben D et al. Head and neck cancer. Lancet 2008; 371: 1695-1709.
3. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirusassociated cancers?. Cancer 2007; 110: 1429-1435.
4. Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol 2008; 5: 24-31.
5. Rampias T, Sasaki C, Weinberger P et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009; 101: 412-423.
6. Weinberger PM, Yu Z, Kountourakis P et al. Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg 2009; 141: 382-389.
7. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-1949.
8. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
9. Stambolic V, MacPherson D, Sas D et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 317-325.
10. Rampias T, Boutati E, Pectasides E et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res 2010; 8: 433-443.
11. Saramaki A, Banwell CM, Campbell MJ et al. Regulation of the human p21(waf1/ cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 2006; 34: 543-554.
12. Takes RP, Rinaldo A, Silver CE et al. Future of the TNM classification and staging system in head and neck cancer. Head Neck 2010; 32: 1693-1711.
13. Shen WH, Balajee AS, Wang J et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157-170.
14. Puc J, Keniry M, Li HS et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005; 7: 193-204.
15. Gu T, Zhang Z, Wang J et al. CREB is a novel nuclear target of PTEN phosphatase. Cancer Res 2011; 71: 2821-2825.
16. Mayo MW, Madrid LV, Westerheide SD et al. PTEN blocks tumor necrosis factorinduced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 2002; 277: 11116-11125.
17. Stransky N, Egloff AM, Tward AD et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-1160.
18. Kurasawa Y, Shiiba M, Nakamura M et al. PTEN expression and methylation status in oral squamous cell carcinoma. Oncol Rep 2008; 19: 1429-1434.
19. Pattje WJ, Schuuring E, Mastik MF et al. The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer. Br J Cancer 2010; 102: 1778-1785.
20. Freeman DJ, Li AG, Wei G et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003; 3: 117-130.
21. Wu X, Hepner K, Castelino-Prabhu S et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci USA 2000; 97: 4233-4238.
22. Vivanco I, Rohle D, Versele M et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci USA 2010; 107: 6459-6464.